ArticleCancer medicine2026
ANKRD62 Modulates NF-κB Signaling to Promote Proliferation and Migration in UCEC.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Members of the ankyrin repeat domain (ANKRD) family are involved in multiple cellular functions, including cell cycle regulation, cell adhesion, and signaling, and have been implicated in the pathogenesis of various cancers. However, the function of ANKRD62, a recently identified member of this family, remains largely unexplored. This study investigated the clinical significance and biological function of ANKRD62 in uterine corpus endometrial carcinoma (UCEC). Through gene expression profiling, we identified ANKRD62 upregulation in UCEC tissues compared to paired adjacent normal tissues. Using overexpression and shRNA-mediated knockdown in cell lines and mouse models, we demonstrated that ANKRD62 is significantly upregulated in UCEC tissues, with expression levels positively correlated with tumor grade and inversely associated with patient survival. In vitro functional assays revealed that ANKRD62 overexpression markedly enhanced UCEC cell proliferation and migration, whereas ANKRD62 knockdown suppressed these malignant phenotypes without significantly affecting apoptosis. Consistent with these findings, in vivo experiments showed that ANKRD62-overexpressing cells exhibited accelerated tumor growth and increased metastatic potential. Mechanistically, ANKRD62 was found to be associated with NF-κB pathway modulation, promoting p65 nuclear translocation and phosphorylation, thereby affecting cellular function. In summary, this study provides the first evidence that ANKRD62 acts as a critical oncogenic driver in UCEC progression and unveils its functional association with NF-κB signaling. These findings highlight the potential of ANKRD62 as a novel therapeutic target and offer new insights into the molecular mechanisms underlying UCEC pathogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.